(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Xilio Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast XLO's revenue for 2024 to be $1,034,204,580, with the lowest XLO revenue forecast at $1,034,204,580, and the highest XLO revenue forecast at $1,034,204,580. On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $2,585,511,450, with the lowest XLO revenue forecast at $2,585,511,450, and the highest XLO revenue forecast at $2,585,511,450.
In 2026, XLO is forecast to generate $430,918,575 in revenue, with the lowest revenue forecast at $430,918,575 and the highest revenue forecast at $430,918,575.